Pennant Group sees FY26 adjusted EPS $1.26-$1.36, consensus $1.31

Sees FY26 revenue $1.13B-$1.17B, consensus $1.15B. Sees FY26 adjusted EBITDA $88.5M-$94.1M. Lynette Walbom, the company’s CFO, also stated, “We believe providing updated annual adjusted consolidated EBITDA guidance in addition to updated annual revenue and adjusted earnings per share guidance is helpful to understanding our expectations for our business and operational cash flow. This updated guidance reflects management’s expectations based on 2025 performance and current operating conditions as well as the impacts of the transaction with UnitedHealth and Amedisys. Our guidance includes revenue in the range of $191.2 to $200.3 million, adjusted EBITDA in the range of $16.7 to $17.9 million, and adjusted EBITDA prior to NCI of $19.8 to $21.1 million relating to these former UnitedHealth and Amedisys assets.”